Moniyot-131 (Sodium Iodide (131i))

The sodium‑iodide symporter in thyroid cells actively transports Sodium Iodide I-131 into the gland. The isotope then emits beta particles that cause localized cellular destruction, while gamma emissions enable imaging of iodine distribution.

The prescribed dose of Moniyot-131 is individualized by the treating physician based on factors such as the specific indication, thyroid size, uptake studies, patient weight, and prior treatments. No standard dose is provided here.

Moniyot-131 is classified as pregnancy category X because the radioactive iodine can harm the developing fetus. It is also not recommended during breastfeeding, as iodine may be secreted in breast milk and expose the infant.

To order Moniyot-131, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Moniyot-131 is comparable to other I‑131 preparations in its mechanism of selective thyroid uptake and beta‑particle emission. Differences may lie in formulation, regulatory approvals, and supplier certifications. GNH India offers an EU‑licensed oral solution that meets Good Distribution Practice standards.

Moniyot-131 should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from moisture, direct sunlight, and physical damage. Follow all local radiation safety regulations when handling the product.

Moniyot-131 is supplied as an oral solution that is taken by mouth under the supervision of a qualified healthcare professional. The exact administration protocol, including fasting status and timing relative to other medications, is determined by the prescribing clinician.

Serious risks include bone marrow suppression, which can lead to anemia, infection or bleeding; radiation thyroiditis causing painful inflammation of the gland; and, in rare cases, pulmonary fibrosis after high cumulative doses. Patients should be monitored closely for these events.

Moniyot-131 should not be used by pregnant or breastfeeding women, individuals with known hypersensitivity to iodine or sodium iodide, patients with severe renal impairment without appropriate monitoring, and those who have not discontinued antithyroid drugs that block iodine uptake.